Connect with us

Government

Biotech Bonanza Will Continue in H2 2020

Biotech Bonanza – Second Half Outlook 2020

Published

on

This article was originally published by Prudent BioTech.

Prudent Biotech ~ IBB Performance 2015 to 2020
 
Close
Prudent Biotech ~ Interest rates
 
Close
 
Close
Prudent Biotech ~ VC Funding
 
Close
Prudent Biotech ~ COVID -19 Testing
 
Close
 
Biotech is one of the rare industries whose prospects have improved as the year has progressed.
 
 
A low interest rate environment, a less hostile regulatory environment, and strong investor interest creates an ideal environment for biotechs to continue outperforming the market.
 
 
Vaccine, treatment and testing companies garner significant interest, but the biotech rally is quite broad-based.
 
 
Biotech exposure is a winning strategy as the group should again have a strong year.
 

Healthcare Pulse

Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achieve. The Nasdaq Biotechnology Index (IBB) finally made a new high after 5 years, eclipsing the level set in July 2015. At the beginning of the year in the Biotech Bonanza 2020 Outlook, a strong case was made for biotech exposure: "The fundamentals for biotechs are stronger than in 2019 as science continues to deliver, acquisitions have acquired a level of urgency, and there is plenty of risk capital to fund biotechs... which are on a trajectory that we believe will finally take the group to an all-time high in the first half." Biotech Bonanza 2020 Outlook, Jan 2020 But that was before the pandemic. The paralyzing viral outbreak that has swept the planet, costing trillions in output and gumming up the wheels of the global economy has also created a confluence of events so very favorable for biotechs that it will continue to push the sector higher up the golden arc.
Prudent Biotech ~ IBB Performance 2015 to 2020
 

Market Moves Higher and The Economy, Well, Will Eventually Follow

The market has concluded that the economy will come around, be it this quarter or next or even the following year. In the meantime, while it waits, the market is surfing the tsunami of fiscal stimulus. And in an irony, the worse the pandemic gets, the more stimulus it triggers. When there is a second wave of viral infections, there will be a second wave of the stimulus. The renewed stimulus will continue to at least support the stock market, if not extend the rally further, even though the worsening pandemic weakens the economic rebound. The recession and the market decline did correct a major technical concern for the stock market. The longest bull market worry is gone, and a new bull market has been born. The market's optimistic outlook of a glass-half-full has allowed it to look past the rising daily cases of infections, which have eclipsed the previous record from March 2020. The next big move for the market can occur when the total infections peak and begin to decline. The market will view that as leading to the second wave of an economic rebound. The fiscal stimulus and the record-low cost of capital will continue to spur risk-taking. The high debt levels that the government incurs is not a concern for the market. In fact, the pandemic may have given a template to shrink future recessions. Throw trillion-dollar stimulus packages to rekindle growth without worrying about deficit. Amidst all the stimulus, it is easy to drown the truth that the recovery path is highly uncertain in no small part due to an ineffective pandemic response which has made the US worse off than many other developed nations. A slower recovery is resulting in a significant and growing cost to the treasury, corporates, people, and the economy. The stimulus and the Federal Reserve's backstopping of the credit markets have avoided a mushrooming of the personal and corporate bankruptcies and economic devastation, at least for now. The second stimulus plan expected to be in place by next month will extend the runway further giving more time to the economy to eventually stage a rebound. The worse will probably occur when the ebbing doses of stimulus expire before a strong and durable economic rebound. This possibility can happen later this year. However, attempting to forecast the path of the economy is nothing but guesswork at this point, simply because of the many unique variables and potential scenarios. It's like peering into a dark well. Earlier this month during an earnings call, JPMorgan Chairman & CEO Jamie Dimon noted : "In a normal recession unemployment goes up, delinquencies go up, charge-offs go up, home prices go down; none of that’s true here...savings are up, incomes are up, home prices are up. So you will see the effect of this recession...you’re going to have a much murkier economic environment going forward than you had in May and June.� Jamie Dimon, Chairman & CEO, JPMorgan The market outlook can brighten immensely when successful vaccine outcomes and targeted treatments are announced, a possibility that can occur in the fourth quarter. This brings us to healthcare and...

The Era of Biotechs

Prudent Biotech ~ COVID -19, Getty Images
 
The biotech group is not only benefiting from the white knight status of being the only industry group, along with pharmaceuticals, that can deliver a solution to the pandemic, but also from a growing risk appetite spurred by a prolonged low cost of capital. In the past, we had highlighted the relationship of biotechs doing best in a prolonged period of low-interest rates. We have entered such a zone this year. When the fed funds rate (2010-2015) was flat after a downward bias...
Prudent Biotech ~ Interest rates
 
...the biotech benchmark rose in a steady long-term uptrend from 2010 to 2015, recording its all-time high in July 2015.
 
Now, as we have entered another prolonged period of low-interest rates, the Nasdaq Biotechnology Index finally made its first new high in 5 years, eclipsing the one set in mid-2015. It doesn't mean there is a perfect causal relationship between interest rates and biotech performance. But at the very least, the correlation underscores the existence of a highly favorable macro environment for biotechs that should now persist for longer than just 2020. As we had noted in our January 2020 outlook: "Perhaps, it is the beginning of a similar longer-term sustained rally [as the one that ended in 2015 which saw the index soaring 400% over 6 years.]" In a stable economy, low-cost money attracts risk-taking. Biotechs are well-positioned to attract such risk capital. In the private market, biopharma venture capital funding has surged this year, almost matching last year's total in just the first half.
Prudent Biotech ~ VC Funding
 
Biopharma Venture Cap Investing, Source: Silicon Valley Bank Such private and public risk capital finds it hard to race into many other industries at the same pace because of the uncertainty of business models during a time when the pandemic has the upper hand. However, even though trial delays will continue to occur, biotechs are relatively less impacted.

Vaccines and Treatments

Each piece of positive milestone news in the vaccine development is a jolt of adrenaline for the market. Key players, including Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), AstraZeneca (AZN) and Oxford, Johnson & Johnson (JNJ), Merck (MRK), and Novavax (NVAX), to name a few well-funded Western players, will continue to have major progress updates in the months ahead. These multiple efforts are crucial for vaccine development which is a road littered with failures. Emergent BioSolutions (EBS) remains a primary outsourcer for vaccine manufacturing while developing its treatment. There are many interesting smaller companies, like Inovio (INO), CureVac (CVAC), Arcturus (ARCT), Vaxart (VXRT), and Altimmune (ALT) to name a few, with vaccine programs as well. But strong funding access is just as important as good trial results and it remains to be seen which companies will still remain with viable programs, combining both results and funding, by the end of the year. Many dedicated viral treatments are being developed and some of the notable ones include the monoclonal antibody treatments from Regeneron Pharmaceuticals (REGN) and Vir Biotechnology (VIR), which is also collaborating with Alnylam Pharmaceuticals (ALNY) to use its platform to develop siRNAs for COVID-19 therapeutics. Regeneron earlier this month moved into Phase 2/3 trials, while Vir is expected to begin Phase 2 in August. Gilead's (GILD) repurposed Remdesivir remains the only approved treatment at this time.

Testing Companies & Suppliers

Testing Companies & Their Suppliers Sensible preventive measures and a wide testing net are two critical blocks of an effective pandemic management response. When done in tandem, they assist in shrinking the viral footprint, still facing risks of flash outbreaks but not crippling blows. Two main testing technologies are being used. Molecular assays, which trace for the COVID-19 viral material in a sample, and immunoassays, which track for specific antigens or antibodies known to be triggered by the virus and are thus look-back tests identifying people who were infected and recovered. In mid-July, management firm McKinsey estimated the US capacity at 3 million to 3.5 million weekly tests, well below the 6 million weekly tests for an economy to open partially. For an economy to be fully reopened, it is estimated that a capacity of 20 million daily tests should exist. This is way beyond the country's present capacity.
Prudent Biotech ~ COVID -19 Testing
 

COVID-19 Molecular Testing Process

The above exhibit highlights the complexity of the testing environment. Constraints to capacity exist at different supply points from more front-line activities like sample collection to back-end processes like the availability of chemical reagents in the lab. McKinsey estimates 20 different reagents and consumables are required for executing a test. And many of them are supply-constrained. That is why there is no magic wand solution to quickly get testing to a 6 million weekly level and higher. A few prominent testing companies and suppliers include Quidel (QDEL), Abbott (ABT), Becton Dickinson (BDX), Luminex (LMNX), Thermo Fisher Scientific (TMO), OPKO Health (OPK), PerkinElmer (PKI), Qiagen (QGEN), GenMark Diagnostics (GNMK), Fulgent Genetics (FLGT), Co-Diagnostics (CODX), Meridian Bioscience (VIVO), and numerous others.

A Subdued Regulatory Environment

Prudent Biotech ~ Healthcare
 
Entering 2020, the biggest risk was a noisier and difficult regulatory environment as healthcare costs are a bipartisan issue and this being an election year. That risk diminished by the end of the first quarter as healthcare has acquired a savior's halo after being placed front-and-center in the pandemic response. President Trump's executive orders last week on drug rebates, insulin, and importation are just low wattage orders that do not move the needle materially on the drug pricing issue and will get tied up in courts. The regulatory environment will remain mild for the remainder of the year and even most likely through most of next year as attention remains diverted until the pandemic has been overcome.

Conclusion

Last month, the prominent Nasdaq Biotechnology Index finally rose to its first new high in five years. Highs that occur after such long periods represent a very meaningful shift in sentiment and can last for many months and years, auguring well for consistent long-term gains. The intrinsic fundamentals of biotechs have never been better as science continues to push new frontiers. Furthermore, the ability of biotechs to manage their business models in a relatively more effective manner during the pandemic than most other industries is a significant benefit and provides a level of comfort, similar to technology, during unprecedented economic uncertainty. The biotechs are also not earnings-driven, but expectations-driven, and with so many vaccines and treatments lining-up, there will be no dearth of news, and quite a bit of it positive. At the beginning of the year, we anticipated the Nasdaq Biotech Index to rise 10%, but now with regulation risk diminished and the pandemic providing an impetus to biotech valuations, we believe the index will be up 20% in 2020. A few promising biotechs and healthcare companies, some of which may be now or in the past part of the Prudent Healthcare or Prudent Biotech or the Smallcap model portfolios, include Regeneron Pharmaceuticals, Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Moderna, Vir Biotechnology, BioMarin Pharmaceutical (BMRN), Emergent BioSolutions, BioNTech, TG Therapeutics (TGTX), Immunomedics (IMMU), Macrogenics (MGNX), Crispr Therapeutics (CRSP), Mersana Therapeutics (MRSN), Novavax, Akero Therapeutics (AKRO), Biohaven Pharma (BHVN), Livongo Health (LVGO), Karuna Therapeutics (KRTX), Halozyme Therapeutics (HALO), Principia Biopharma (PRNB), Trillium Therapeutics (TRIL), Celldex (CLDX), Five Point Therapeutics (FPRX), Ideaya Biosciences (IDYA), Quidel, Luminex, OPKO Health, Akebia Therapeutics (AKBA), NeoGenomics (NEO), Vapotherm (VAPO), Covetrus (CVET), and Meridian Biosciences. Industry exposure can also be acquired through ETFs like the one tracking the Nasdaq Biotech Index and another tracking the S&P Biotechnology Select (XBI). Biotech investing is volatile and high-risk. Investors should pursue a concrete investment strategy preferring a portfolio approach by investing in a basket of promising biotech companies that can assist in managing risk and overcoming mistakes.
The post Biotech Bonanza – Second Half Outlook 2020 appeared first on Prudent Biotech.

Read More

Continue Reading

International

Four Years Ago This Week, Freedom Was Torched

Four Years Ago This Week, Freedom Was Torched

Authored by Jeffrey Tucker via The Brownstone Institute,

"Beware the Ides of March,” Shakespeare…

Published

on

Four Years Ago This Week, Freedom Was Torched

Authored by Jeffrey Tucker via The Brownstone Institute,

"Beware the Ides of March,” Shakespeare quotes the soothsayer’s warning Julius Caesar about what turned out to be an impending assassination on March 15. The death of American liberty happened around the same time four years ago, when the orders went out from all levels of government to close all indoor and outdoor venues where people gather. 

It was not quite a law and it was never voted on by anyone. Seemingly out of nowhere, people who the public had largely ignored, the public health bureaucrats, all united to tell the executives in charge – mayors, governors, and the president – that the only way to deal with a respiratory virus was to scrap freedom and the Bill of Rights. 

And they did, not only in the US but all over the world. 

The forced closures in the US began on March 6 when the mayor of Austin, Texas, announced the shutdown of the technology and arts festival South by Southwest. Hundreds of thousands of contracts, of attendees and vendors, were instantly scrapped. The mayor said he was acting on the advice of his health experts and they in turn pointed to the CDC, which in turn pointed to the World Health Organization, which in turn pointed to member states and so on. 

There was no record of Covid in Austin, Texas, that day but they were sure they were doing their part to stop the spread. It was the first deployment of the “Zero Covid” strategy that became, for a time, official US policy, just as in China. 

It was never clear precisely who to blame or who would take responsibility, legal or otherwise. 

This Friday evening press conference in Austin was just the beginning. By the next Thursday evening, the lockdown mania reached a full crescendo. Donald Trump went on nationwide television to announce that everything was under control but that he was stopping all travel in and out of US borders, from Europe, the UK, Australia, and New Zealand. American citizens would need to return by Monday or be stuck. 

Americans abroad panicked while spending on tickets home and crowded into international airports with waits up to 8 hours standing shoulder to shoulder. It was the first clear sign: there would be no consistency in the deployment of these edicts. 

There is no historical record of any American president ever issuing global travel restrictions like this without a declaration of war. Until then, and since the age of travel began, every American had taken it for granted that he could buy a ticket and board a plane. That was no longer possible. Very quickly it became even difficult to travel state to state, as most states eventually implemented a two-week quarantine rule. 

The next day, Friday March 13, Broadway closed and New York City began to empty out as any residents who could went to summer homes or out of state. 

On that day, the Trump administration declared the national emergency by invoking the Stafford Act which triggers new powers and resources to the Federal Emergency Management Administration. 

In addition, the Department of Health and Human Services issued a classified document, only to be released to the public months later. The document initiated the lockdowns. It still does not exist on any government website.

The White House Coronavirus Response Task Force, led by the Vice President, will coordinate a whole-of-government approach, including governors, state and local officials, and members of Congress, to develop the best options for the safety, well-being, and health of the American people. HHS is the LFA [Lead Federal Agency] for coordinating the federal response to COVID-19.

Closures were guaranteed:

Recommend significantly limiting public gatherings and cancellation of almost all sporting events, performances, and public and private meetings that cannot be convened by phone. Consider school closures. Issue widespread ‘stay at home’ directives for public and private organizations, with nearly 100% telework for some, although critical public services and infrastructure may need to retain skeleton crews. Law enforcement could shift to focus more on crime prevention, as routine monitoring of storefronts could be important.

In this vision of turnkey totalitarian control of society, the vaccine was pre-approved: “Partner with pharmaceutical industry to produce anti-virals and vaccine.”

The National Security Council was put in charge of policy making. The CDC was just the marketing operation. That’s why it felt like martial law. Without using those words, that’s what was being declared. It even urged information management, with censorship strongly implied.

The timing here is fascinating. This document came out on a Friday. But according to every autobiographical account – from Mike Pence and Scott Gottlieb to Deborah Birx and Jared Kushner – the gathered team did not meet with Trump himself until the weekend of the 14th and 15th, Saturday and Sunday. 

According to their account, this was his first real encounter with the urge that he lock down the whole country. He reluctantly agreed to 15 days to flatten the curve. He announced this on Monday the 16th with the famous line: “All public and private venues where people gather should be closed.”

This makes no sense. The decision had already been made and all enabling documents were already in circulation. 

There are only two possibilities. 

One: the Department of Homeland Security issued this March 13 HHS document without Trump’s knowledge or authority. That seems unlikely. 

Two: Kushner, Birx, Pence, and Gottlieb are lying. They decided on a story and they are sticking to it. 

Trump himself has never explained the timeline or precisely when he decided to greenlight the lockdowns. To this day, he avoids the issue beyond his constant claim that he doesn’t get enough credit for his handling of the pandemic.

With Nixon, the famous question was always what did he know and when did he know it? When it comes to Trump and insofar as concerns Covid lockdowns – unlike the fake allegations of collusion with Russia – we have no investigations. To this day, no one in the corporate media seems even slightly interested in why, how, or when human rights got abolished by bureaucratic edict. 

As part of the lockdowns, the Cybersecurity and Infrastructure Security Agency, which was and is part of the Department of Homeland Security, as set up in 2018, broke the entire American labor force into essential and nonessential.

They also set up and enforced censorship protocols, which is why it seemed like so few objected. In addition, CISA was tasked with overseeing mail-in ballots. 

Only 8 days into the 15, Trump announced that he wanted to open the country by Easter, which was on April 12. His announcement on March 24 was treated as outrageous and irresponsible by the national press but keep in mind: Easter would already take us beyond the initial two-week lockdown. What seemed to be an opening was an extension of closing. 

This announcement by Trump encouraged Birx and Fauci to ask for an additional 30 days of lockdown, which Trump granted. Even on April 23, Trump told Georgia and Florida, which had made noises about reopening, that “It’s too soon.” He publicly fought with the governor of Georgia, who was first to open his state. 

Before the 15 days was over, Congress passed and the president signed the 880-page CARES Act, which authorized the distribution of $2 trillion to states, businesses, and individuals, thus guaranteeing that lockdowns would continue for the duration. 

There was never a stated exit plan beyond Birx’s public statements that she wanted zero cases of Covid in the country. That was never going to happen. It is very likely that the virus had already been circulating in the US and Canada from October 2019. A famous seroprevalence study by Jay Bhattacharya came out in May 2020 discerning that infections and immunity were already widespread in the California county they examined. 

What that implied was two crucial points: there was zero hope for the Zero Covid mission and this pandemic would end as they all did, through endemicity via exposure, not from a vaccine as such. That was certainly not the message that was being broadcast from Washington. The growing sense at the time was that we all had to sit tight and just wait for the inoculation on which pharmaceutical companies were working. 

By summer 2020, you recall what happened. A restless generation of kids fed up with this stay-at-home nonsense seized on the opportunity to protest racial injustice in the killing of George Floyd. Public health officials approved of these gatherings – unlike protests against lockdowns – on grounds that racism was a virus even more serious than Covid. Some of these protests got out of hand and became violent and destructive. 

Meanwhile, substance abuse rage – the liquor and weed stores never closed – and immune systems were being degraded by lack of normal exposure, exactly as the Bakersfield doctors had predicted. Millions of small businesses had closed. The learning losses from school closures were mounting, as it turned out that Zoom school was near worthless. 

It was about this time that Trump seemed to figure out – thanks to the wise council of Dr. Scott Atlas – that he had been played and started urging states to reopen. But it was strange: he seemed to be less in the position of being a president in charge and more of a public pundit, Tweeting out his wishes until his account was banned. He was unable to put the worms back in the can that he had approved opening. 

By that time, and by all accounts, Trump was convinced that the whole effort was a mistake, that he had been trolled into wrecking the country he promised to make great. It was too late. Mail-in ballots had been widely approved, the country was in shambles, the media and public health bureaucrats were ruling the airwaves, and his final months of the campaign failed even to come to grips with the reality on the ground. 

At the time, many people had predicted that once Biden took office and the vaccine was released, Covid would be declared to have been beaten. But that didn’t happen and mainly for one reason: resistance to the vaccine was more intense than anyone had predicted. The Biden administration attempted to impose mandates on the entire US workforce. Thanks to a Supreme Court ruling, that effort was thwarted but not before HR departments around the country had already implemented them. 

As the months rolled on – and four major cities closed all public accommodations to the unvaccinated, who were being demonized for prolonging the pandemic – it became clear that the vaccine could not and would not stop infection or transmission, which means that this shot could not be classified as a public health benefit. Even as a private benefit, the evidence was mixed. Any protection it provided was short-lived and reports of vaccine injury began to mount. Even now, we cannot gain full clarity on the scale of the problem because essential data and documentation remains classified. 

After four years, we find ourselves in a strange position. We still do not know precisely what unfolded in mid-March 2020: who made what decisions, when, and why. There has been no serious attempt at any high level to provide a clear accounting much less assign blame. 

Not even Tucker Carlson, who reportedly played a crucial role in getting Trump to panic over the virus, will tell us the source of his own information or what his source told him. There have been a series of valuable hearings in the House and Senate but they have received little to no press attention, and none have focus on the lockdown orders themselves. 

The prevailing attitude in public life is just to forget the whole thing. And yet we live now in a country very different from the one we inhabited five years ago. Our media is captured. Social media is widely censored in violation of the First Amendment, a problem being taken up by the Supreme Court this month with no certainty of the outcome. The administrative state that seized control has not given up power. Crime has been normalized. Art and music institutions are on the rocks. Public trust in all official institutions is at rock bottom. We don’t even know if we can trust the elections anymore. 

In the early days of lockdown, Henry Kissinger warned that if the mitigation plan does not go well, the world will find itself set “on fire.” He died in 2023. Meanwhile, the world is indeed on fire. The essential struggle in every country on earth today concerns the battle between the authority and power of permanent administration apparatus of the state – the very one that took total control in lockdowns – and the enlightenment ideal of a government that is responsible to the will of the people and the moral demand for freedom and rights. 

How this struggle turns out is the essential story of our times. 

CODA: I’m embedding a copy of PanCAP Adapted, as annotated by Debbie Lerman. You might need to download the whole thing to see the annotations. If you can help with research, please do.

*  *  *

Jeffrey Tucker is the author of the excellent new book 'Life After Lock-Down'

Tyler Durden Mon, 03/11/2024 - 23:40

Read More

Continue Reading

Government

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A…

Published

on

CDC Warns Thousands Of Children Sent To ER After Taking Common Sleep Aid

Authored by Jack Phillips via The Epoch Times (emphasis ours),

A U.S. Centers for Disease Control (CDC) paper released Thursday found that thousands of young children have been taken to the emergency room over the past several years after taking the very common sleep-aid supplement melatonin.

The Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia, on April 23, 2020. (Tami Chappell/AFP via Getty Images)

The agency said that melatonin, which can come in gummies that are meant for adults, was implicated in about 7 percent of all emergency room visits for young children and infants “for unsupervised medication ingestions,” adding that many incidents were linked to the ingestion of gummy formulations that were flavored. Those incidents occurred between the years 2019 and 2022.

Melatonin is a hormone produced by the human body to regulate its sleep cycle. Supplements, which are sold in a number of different formulas, are generally taken before falling asleep and are popular among people suffering from insomnia, jet lag, chronic pain, or other problems.

The supplement isn’t regulated by the U.S. Food and Drug Administration and does not require child-resistant packaging. However, a number of supplement companies include caps or lids that are difficult for children to open.

The CDC report said that a significant number of melatonin-ingestion cases among young children were due to the children opening bottles that had not been properly closed or were within their reach. Thursday’s report, the agency said, “highlights the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight,” including melatonin.

The approximately 11,000 emergency department visits for unsupervised melatonin ingestions by infants and young children during 2019–2022 highlight the importance of educating parents and other caregivers about keeping all medications and supplements (including gummies) out of children’s reach and sight.

The CDC notes that melatonin use among Americans has increased five-fold over the past 25 years or so. That has coincided with a 530 percent increase in poison center calls for melatonin exposures to children between 2012 and 2021, it said, as well as a 420 percent increase in emergency visits for unsupervised melatonin ingestion by young children or infants between 2009 and 2020.

Some health officials advise that children under the age of 3 should avoid taking melatonin unless a doctor says otherwise. Side effects include drowsiness, headaches, agitation, dizziness, and bed wetting.

Other symptoms of too much melatonin include nausea, diarrhea, joint pain, anxiety, and irritability. The supplement can also impact blood pressure.

However, there is no established threshold for a melatonin overdose, officials have said. Most adult melatonin supplements contain a maximum of 10 milligrams of melatonin per serving, and some contain less.

Many people can tolerate even relatively large doses of melatonin without significant harm, officials say. But there is no antidote for an overdose. In cases of a child accidentally ingesting melatonin, doctors often ask a reliable adult to monitor them at home.

Dr. Cora Collette Breuner, with the Seattle Children’s Hospital at the University of Washington, told CNN that parents should speak with a doctor before giving their children the supplement.

“I also tell families, this is not something your child should take forever. Nobody knows what the long-term effects of taking this is on your child’s growth and development,” she told the outlet. “Taking away blue-light-emitting smartphones, tablets, laptops, and television at least two hours before bed will keep melatonin production humming along, as will reading or listening to bedtime stories in a softly lit room, taking a warm bath, or doing light stretches.”

In 2022, researchers found that in 2021, U.S. poison control centers received more than 52,000 calls about children consuming worrisome amounts of the dietary supplement. That’s a six-fold increase from about a decade earlier. Most such calls are about young children who accidentally got into bottles of melatonin, some of which come in the form of gummies for kids, the report said.

Dr. Karima Lelak, an emergency physician at Children’s Hospital of Michigan and the lead author of the study published in 2022 by the CDC, found that in about 83 percent of those calls, the children did not show any symptoms.

However, other children had vomiting, altered breathing, or other symptoms. Over the 10 years studied, more than 4,000 children were hospitalized, five were put on machines to help them breathe, and two children under the age of two died. Most of the hospitalized children were teenagers, and many of those ingestions were thought to be suicide attempts.

Those researchers also suggested that COVID-19 lockdowns and virtual learning forced more children to be at home all day, meaning there were more opportunities for kids to access melatonin. Also, those restrictions may have caused sleep-disrupting stress and anxiety, leading more families to consider melatonin, they suggested.

The Associated Press contributed to this report.

Tyler Durden Mon, 03/11/2024 - 21:40

Read More

Continue Reading

International

Red Candle In The Wind

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by…

Published

on

Red Candle In The Wind

By Benjamin PIcton of Rabobank

February non-farm payrolls superficially exceeded market expectations on Friday by printing at 275,000 against a consensus call of 200,000. We say superficially, because the downward revisions to prior months totalled 167,000 for December and January, taking the total change in employed persons well below the implied forecast, and helping the unemployment rate to pop two-ticks to 3.9%. The U6 underemployment rate also rose from 7.2% to 7.3%, while average hourly earnings growth fell to 0.2% m-o-m and average weekly hours worked languished at 34.3, equalling pre-pandemic lows.

Undeterred by the devil in the detail, the algos sprang into action once exchanges opened. Market darling NVIDIA hit a new intraday high of $974 before (presumably) the humans took over and sold the stock down more than 10% to close at $875.28. If our suspicions are correct that it was the AIs buying before the humans started selling (no doubt triggering trailing stops on the way down), the irony is not lost on us.

The 1-day chart for NVIDIA now makes for interesting viewing, because the red candle posted on Friday presents quite a strong bearish engulfing signal. Volume traded on the day was almost double the 15-day simple moving average, and similar price action is observable on the 1-day charts for both Intel and AMD. Regular readers will be aware that we have expressed incredulity in the past about the durability the AI thematic melt-up, so it will be interesting to see whether Friday’s sell off is just a profit-taking blip, or a genuine trend reversal.

AI equities aside, this week ought to be important for markets because the BTFP program expires today. That means that the Fed will no longer be loaning cash to the banking system in exchange for collateral pledged at-par. The KBW Regional Banking index has so far taken this in its stride and is trading 30% above the lows established during the mini banking crisis of this time last year, but the Fed’s liquidity facility was effectively an exercise in can-kicking that makes regional banks a sector of the market worth paying attention to in the weeks ahead. Even here in Sydney, regulators are warning of external risks posed to the banking sector from scheduled refinancing of commercial real estate loans following sharp falls in valuations.

Markets are sending signals in other sectors, too. Gold closed at a new record-high of $2178/oz on Friday after trading above $2200/oz briefly. Gold has been going ballistic since the Friday before last, posting gains even on days where 2-year Treasury yields have risen. Gold bugs are buying as real yields fall from the October highs and inflation breakevens creep higher. This is particularly interesting as gold ETFs have been recording net outflows; suggesting that price gains aren’t being driven by a retail pile-in. Are gold buyers now betting on a stagflationary outcome where the Fed cuts without inflation being anchored at the 2% target? The price action around the US CPI release tomorrow ought to be illuminating.

Leaving the day-to-day movements to one side, we are also seeing further signs of structural change at the macro level. The UK budget last week included a provision for the creation of a British ISA. That is, an Individual Savings Account that provides tax breaks to savers who invest their money in the stock of British companies. This follows moves last year to encourage pension funds to head up the risk curve by allocating 5% of their capital to unlisted investments.

As a Hail Mary option for a government cruising toward an electoral drubbing it’s a curious choice, but it’s worth highlighting as cash-strapped governments increasingly see private savings pools as a funding solution for their spending priorities.

Of course, the UK is not alone in making creeping moves towards financial repression. In contrast to announcements today of increased trade liberalisation, Australian Treasurer Jim Chalmers has in the recent past flagged his interest in tapping private pension savings to fund state spending priorities, including defence, public housing and renewable energy projects. Both the UK and Australia appear intent on finding ways to open up the lungs of their economies, but government wants more say in directing private capital flows for state goals.

So, how far is the blurring of the lines between free markets and state planning likely to go? Given the immense and varied budgetary (and security) pressures that governments are facing, could we see a re-up of WWII-era Victory bonds, where private investors are encouraged to do their patriotic duty by directly financing government at negative real rates?

That would really light a fire under the gold market.

Tyler Durden Mon, 03/11/2024 - 19:00

Read More

Continue Reading

Trending